NCT06315491 - A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Platinum-resistant Ovarian CancerRefractory Ovarian Carcinoma

Interventions

DRUG

CBX-12

CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.

Trial Locations (17)

10016

ACTIVE_NOT_RECRUITING

Pci Nyu Langone Health, New York

10021

ACTIVE_NOT_RECRUITING

Albert Einstein College of Medicine Montefiore Medical, New York

15212

RECRUITING

Allegheny Singer Research Institute D/B/A Ahn Research Institution, Pittsburgh

33063

ACTIVE_NOT_RECRUITING

D&H Cancer Research Center, Margate

33606

ACTIVE_NOT_RECRUITING

South Florida Gynecology, Tampa

40202

ACTIVE_NOT_RECRUITING

Norton Cancer Institute, Louisville

44106

ACTIVE_NOT_RECRUITING

University Hospitals Seidman Cancer Center, Cleveland

46311

WITHDRAWN

Northwest Cancer Centers, Dyer

70433

ACTIVE_NOT_RECRUITING

Women's Cancer Care, Covington

75251

RECRUITING

Mary Crowley Cancer Research, Dallas

77380

ACTIVE_NOT_RECRUITING

Texas Oncology- Gulf Coast, The Woodlands

85260

WITHDRAWN

Honor Health, Scottsdale

85711

ACTIVE_NOT_RECRUITING

Arizona Oncology Associates, Tucson

90033

ACTIVE_NOT_RECRUITING

Usc Norris Comprehensive Cancer Center, Los Angeles

97401

ACTIVE_NOT_RECRUITING

Oncology Associates of Oregon, Eugene

98405

ACTIVE_NOT_RECRUITING

Multicare Institute For Research & Innovation, Tacoma

06510

ACTIVE_NOT_RECRUITING

Yale University School of Medicine, New Haven